Valeant moves forward with premerger notification to FTC, Allergan holds its own
- Valeant has filed an investor presentation with the Securities and Exchange Commission (SEC).
- Allergan continues to resist a merger with Valeant, calling Valeant’s business model “unsustainable.”
- In response to claims of a lack of transparency, Valeant has promised to disclose sales of its top 15 products.
Allergan is attempting to hold its own against the latest aggressive moves by Valeant. Allergan is focusing on Valeant’s business model, which it characterizes as unsustainable, citing “anemic” organic growth.
On June 10, 2014, Allergan files an investor presentation in which it outlined its concerns about Valeant’s business fundamentals and lack of transparency. Valeant has asserted that 13 of its top 15 products are growing, however, the company has yet to deliver data to support this claim. During the upcoming second-quarter sales performance call, Valeant plans to provide sales, price and volume-related information on its top-selling products.
- www.finanznachrichten.de Allergan reiterates belief that Valeant’s business model unsustainable